An experimental heart drug from GlaxoSmithKline failed to work as hoped in the first part of a large clinical trial, the company said on Tuesday, dealing a blow to its pipeline of new medicines. Losmapimod was being assessed as a treatment to reduce the risk of further cardiovascular problems after heart attacks, but it failed to show the hoped-for benefits and GSK said the result did not support investment in a larger second part of the study.